Fat clearances and hyperlipidaemia in renal allograft recipients--the role of insulin resistance

Clinica Chimica Acta; International Journal of Clinical Chemistry
M K ChanJ F Moorhead

Abstract

The mechanism of hyperlipidaemia in renal allograft recipients was investigated in 19 patients randomly selected from a cohort of 54 patients with functioning renal allografts. Serum cholesterol, triglyceride and high-density lipoprotein cholesterol concentrations as well as plasma immunoreactive insulin levels were measured in fasting blood samples. Intravenous fat tolerance tests were performed before and 15 min after heparin administration. Renal allograft recipients had reduced fractional clearance rates of Intralipid and a positive correlation was demonstrated between plasma immunoreactive insulin levels and serum triglyceride concentrations. Plasma immunoreactive insulins also correlated inversely with fractional clearance rates of Intralipid. It was concluded that both increased production and decreased removal of lipoproteins contribute to the hyperlipidaemia and that insulin resistance due to corticosteroids was the centre of the problem.

References

May 6, 1975·European Journal of Biochemistry·S Diamant, E Shafrir
Jan 1, 1978·Nephron·C PonticelliM Cecchettin
Mar 23, 1974·Lancet·A CasarettoD Bagdade
Jan 1, 1969·Acta Endocrinologica. Supplementum·A R MidgleyG D Niswender
Nov 20, 1980·Clinica Chimica Acta; International Journal of Clinical Chemistry·M K ChanJ F Moorhead

❮ Previous
Next ❯

Citations

Sep 15, 1982·Clinica Chimica Acta; International Journal of Clinical Chemistry·M K ChanJ F Moorhead
Aug 31, 1992·Clinica Chimica Acta; International Journal of Clinical Chemistry·C L MalmendierH Bismuth
Jan 12, 2002·Kidney International·Bertram L Kasiske

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.